Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia

Am J Physiol Heart Circ Physiol. 2016 Dec 1;311(6):H1339-H1351. doi: 10.1152/ajpheart.00458.2015. Epub 2016 Sep 2.

Abstract

Coronary microvascular dysfunction (CMD) has been proposed as an important component of diabetes mellitus (DM)- and hypercholesterolemia-associated coronary artery disease (CAD). Previously we observed that 2.5 mo of DM and high-fat diet (HFD) in swine blunted bradykinin (BK)-induced vasodilation and attenuated endothelin (ET)-1-mediated vasoconstriction. Here we studied the progression of CMD after 15 mo in the same animal model of CAD. Ten male swine were fed a HFD in the absence (HFD, n = 5) or presence of streptozotocin-induced DM (DM + HFD, n = 5). Responses of small (∼300-μm-diameter) coronary arteries to BK, ET-1, and the nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine were examined in vitro and compared with those of healthy (Normal) swine (n = 12). Blood glucose was elevated in DM + HFD (17.6 ± 4.5 mmol/l) compared with HFD (5.1 ± 0.4 mmol/l) and Normal (5.8 ± 0.6 mmol/l) swine, while cholesterol was markedly elevated in DM + HFD (16.8 ± 1.7 mmol/l) and HFD (18.1 ± 2.6 mmol/l) compared with Normal (2.1 ± 0.2 mmol/l) swine (all P < 0.05). Small coronary arteries showed early atherosclerotic plaques in HFD and DM + HFD swine. Surprisingly, DM + HFD and HFD swine maintained BK responsiveness compared with Normal swine due to an increase in NO availability relative to endothelium-derived hyperpolarizing factors. However, ET-1 responsiveness was greater in HFD and DM + HFD than Normal swine (both P < 0.05), resulting mainly from ETB receptor-mediated vasoconstriction. Moreover, the calculated vascular stiffness coefficient was higher in DM + HFD and HFD than Normal swine (both P < 0.05). In conclusion, 15 mo of DM + HFD, as well as HFD alone, resulted in CMD. Although the overall vasodilation to BK was unperturbed, the relative contributions of NO and endothelium-derived hyperpolarizing factor pathways were altered. Moreover, the vasoconstrictor response to ET-1 was enhanced, involving the ETB receptors. In conjunction with our previous study, these findings highlight the time dependence of the phenotype of CMD.

Keywords: coronary microvascular dysfunction; diabetes; endothelin-1; hypercholesterolemia; swine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bradykinin / pharmacology
  • Coronary Vessels / drug effects*
  • Coronary Vessels / metabolism
  • Coronary Vessels / pathology
  • Coronary Vessels / physiopathology
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / physiopathology*
  • Diet, High-Fat
  • Endothelin-1 / pharmacology
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / genetics
  • Hypercholesterolemia / metabolism
  • Hypercholesterolemia / physiopathology*
  • Intermediate-Conductance Calcium-Activated Potassium Channels / genetics
  • Large-Conductance Calcium-Activated Potassium Channels / genetics
  • Male
  • Microvessels / drug effects*
  • Microvessels / metabolism
  • Microvessels / pathology
  • Microvessels / physiopathology
  • Nitric Oxide / metabolism
  • Plaque, Atherosclerotic / pathology
  • Real-Time Polymerase Chain Reaction
  • Receptor, Endothelin A / genetics
  • Receptor, Endothelin B / genetics
  • S-Nitroso-N-Acetylpenicillamine / pharmacology
  • Small-Conductance Calcium-Activated Potassium Channels / genetics
  • Sus scrofa
  • Swine
  • Vasoconstriction / drug effects*
  • Vasoconstriction / physiology
  • Vasodilation / drug effects*
  • Vasodilation / physiology
  • Vasodilator Agents / pharmacology*

Substances

  • Endothelin-1
  • Intermediate-Conductance Calcium-Activated Potassium Channels
  • Large-Conductance Calcium-Activated Potassium Channels
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Small-Conductance Calcium-Activated Potassium Channels
  • Vasodilator Agents
  • Nitric Oxide
  • S-Nitroso-N-Acetylpenicillamine
  • Bradykinin